<DOC>
	<DOCNO>NCT00020696</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine tirapazamine cisplatin treat patient recurrent ovarian epithelial primary peritoneal cancer .</brief_summary>
	<brief_title>Tirapazamine Plus Cisplatin Treating Patients With Persistent Recurrent Ovarian Epithelial Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity tirapazamine cisplatin patient persistent recurrent platinum-sensitive ovarian epithelial primary peritoneal carcinoma . - Determine nature degree toxicity regimen patient . OUTLINE : This multicenter study . Patients receive tirapazamine IV 2 hour follow 1 hour later cisplatin IV 30 minute day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 20-65 patient accrue study .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm persistent recurrent ovarian epithelial primary peritoneal carcinoma At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan Platinumsensitive disease Treatmentfree interval 6 month without clinical evidence progressive disease response platinum compound One prior chemotherapy regimen contain cisplatin another platinum compound primary disease require Initial treatment may include highdose therapy , consolidation , extend therapy administer surgical nonsurgical assessment Patients previously treat paclitaxel may receive second regimen contain paclitaxel No additional cytotoxic chemotherapy ( include retreatment initial regimen ) recurrent persistent disease Ineligible high priority GOG protocol ( active GOG phase III protocol patient population ) Treatmentfree interval 12 month nonplatinumbased GOG0146 series protocol active concurrently protocol PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No prior concurrent myocardial infarction ischemic heart disease Other : No active infection require antibiotic No sensory motor neuropathy great grade 1 No invasive malignancy within past 5 year except nonmelanoma skin cancer Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic immunological agent direct malignant tumor Chemotherapy : See Disease Characteristics Recovered prior chemotherapy No prior tirapazamine Endocrine therapy : At least 1 week since prior hormonal therapy direct malignant tumor Concurrent hormone replacement therapy allow Radiotherapy : Recovered prior radiotherapy No prior radiotherapy site ( ) measurable disease use study No prior radiotherapy 25 % bone marrow Surgery : See Disease Characteristics Recovered prior surgery Other : No prior cancer treatment would preclude study At least 3 week since prior therapy direct malignant tumor</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>